vs

Side-by-side financial comparison of CODEXIS, INC. (CDXS) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.

CODEXIS, INC. is the larger business by last-quarter revenue ($38.9M vs $20.3M, roughly 1.9× Ispire Technology Inc.). CODEXIS, INC. runs the higher net margin — 24.7% vs -32.5%, a 57.2% gap on every dollar of revenue. On growth, CODEXIS, INC. posted the faster year-over-year revenue change (81.3% vs -51.5%). CODEXIS, INC. produced more free cash flow last quarter ($19.6M vs $-4.0M). Over the past eight quarters, CODEXIS, INC.'s revenue compounded faster (51.0% CAGR vs -17.8%).

Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

CDXS vs ISPR — Head-to-Head

Bigger by revenue
CDXS
CDXS
1.9× larger
CDXS
$38.9M
$20.3M
ISPR
Growing faster (revenue YoY)
CDXS
CDXS
+132.8% gap
CDXS
81.3%
-51.5%
ISPR
Higher net margin
CDXS
CDXS
57.2% more per $
CDXS
24.7%
-32.5%
ISPR
More free cash flow
CDXS
CDXS
$23.6M more FCF
CDXS
$19.6M
$-4.0M
ISPR
Faster 2-yr revenue CAGR
CDXS
CDXS
Annualised
CDXS
51.0%
-17.8%
ISPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
CDXS
CDXS
ISPR
ISPR
Revenue
$38.9M
$20.3M
Net Profit
$9.6M
$-6.6M
Gross Margin
94.8%
17.1%
Operating Margin
27.1%
-33.9%
Net Margin
24.7%
-32.5%
Revenue YoY
81.3%
-51.5%
Net Profit YoY
192.5%
17.4%
EPS (diluted)
$0.13
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDXS
CDXS
ISPR
ISPR
Q4 25
$38.9M
$20.3M
Q3 25
$8.6M
$30.4M
Q2 25
$15.3M
$20.1M
Q1 25
$7.5M
$26.2M
Q4 24
$21.5M
$41.8M
Q3 24
$12.8M
$39.3M
Q2 24
$8.0M
$37.3M
Q1 24
$17.1M
$30.0M
Net Profit
CDXS
CDXS
ISPR
ISPR
Q4 25
$9.6M
$-6.6M
Q3 25
$-19.6M
$-3.3M
Q2 25
$-13.3M
$-14.8M
Q1 25
$-20.7M
$-10.9M
Q4 24
$-10.4M
$-8.0M
Q3 24
$-20.6M
$-5.6M
Q2 24
$-22.8M
$-3.5M
Q1 24
$-11.5M
$-5.9M
Gross Margin
CDXS
CDXS
ISPR
ISPR
Q4 25
94.8%
17.1%
Q3 25
71.3%
17.0%
Q2 25
86.3%
12.3%
Q1 25
63.8%
18.2%
Q4 24
83.0%
18.5%
Q3 24
66.4%
19.5%
Q2 24
56.6%
28.3%
Q1 24
71.6%
20.4%
Operating Margin
CDXS
CDXS
ISPR
ISPR
Q4 25
27.1%
-33.9%
Q3 25
-220.3%
-8.9%
Q2 25
-83.9%
-72.7%
Q1 25
-271.6%
-40.4%
Q4 24
-34.2%
-17.6%
Q3 24
-129.0%
-13.4%
Q2 24
-284.9%
-9.2%
Q1 24
-69.6%
-18.8%
Net Margin
CDXS
CDXS
ISPR
ISPR
Q4 25
24.7%
-32.5%
Q3 25
-228.1%
-10.7%
Q2 25
-86.6%
-73.4%
Q1 25
-274.3%
-41.5%
Q4 24
-48.4%
-19.1%
Q3 24
-160.8%
-14.2%
Q2 24
-285.2%
-9.4%
Q1 24
-67.4%
-19.7%
EPS (diluted)
CDXS
CDXS
ISPR
ISPR
Q4 25
$0.13
$-0.12
Q3 25
$-0.22
$-0.06
Q2 25
$-0.16
$-0.26
Q1 25
$-0.25
$-0.19
Q4 24
$-0.12
$-0.14
Q3 24
$-0.29
$-0.10
Q2 24
$-0.32
$-0.07
Q1 24
$-0.16
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDXS
CDXS
ISPR
ISPR
Cash + ST InvestmentsLiquidity on hand
$78.2M
$17.6M
Total DebtLower is stronger
$40.1M
Stockholders' EquityBook value
$50.5M
$-7.7M
Total Assets
$147.8M
$84.4M
Debt / EquityLower = less leverage
0.79×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDXS
CDXS
ISPR
ISPR
Q4 25
$78.2M
$17.6M
Q3 25
$58.7M
$22.7M
Q2 25
$66.3M
$24.4M
Q1 25
$59.8M
$23.5M
Q4 24
$73.5M
$34.4M
Q3 24
$90.3M
$37.7M
Q2 24
$73.2M
$35.1M
Q1 24
$85.5M
$39.5M
Total Debt
CDXS
CDXS
ISPR
ISPR
Q4 25
$40.1M
Q3 25
$39.7M
Q2 25
$39.4M
Q1 25
$29.2M
Q4 24
$28.9M
Q3 24
$28.6M
Q2 24
$28.4M
Q1 24
$28.1M
Stockholders' Equity
CDXS
CDXS
ISPR
ISPR
Q4 25
$50.5M
$-7.7M
Q3 25
$38.5M
$-1.8M
Q2 25
$55.6M
$604.7K
Q1 25
$49.6M
$14.8M
Q4 24
$66.9M
$24.2M
Q3 24
$73.4M
$30.7M
Q2 24
$61.4M
$34.5M
Q1 24
$79.3M
$35.9M
Total Assets
CDXS
CDXS
ISPR
ISPR
Q4 25
$147.8M
$84.4M
Q3 25
$124.0M
$96.4M
Q2 25
$138.2M
$102.2M
Q1 25
$128.9M
$115.7M
Q4 24
$149.0M
$132.0M
Q3 24
$148.2M
$129.0M
Q2 24
$132.0M
$122.6M
Q1 24
$149.6M
$108.0M
Debt / Equity
CDXS
CDXS
ISPR
ISPR
Q4 25
0.79×
Q3 25
1.03×
Q2 25
0.71×
Q1 25
0.59×
Q4 24
0.43×
Q3 24
0.39×
Q2 24
0.46×
Q1 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDXS
CDXS
ISPR
ISPR
Operating Cash FlowLast quarter
$20.1M
$-4.0M
Free Cash FlowOCF − Capex
$19.6M
$-4.0M
FCF MarginFCF / Revenue
50.3%
-19.9%
Capex IntensityCapex / Revenue
1.3%
0.3%
Cash ConversionOCF / Net Profit
2.09×
TTM Free Cash FlowTrailing 4 quarters
$-23.8M
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDXS
CDXS
ISPR
ISPR
Q4 25
$20.1M
$-4.0M
Q3 25
$-7.7M
$-1.2M
Q2 25
$-18.0M
$4.7M
Q1 25
$-13.8M
$-12.5M
Q4 24
$-16.5M
$-3.2M
Q3 24
$-13.0M
$3.6M
Q2 24
$-12.2M
$-1.4M
Q1 24
$-7.8M
$3.4M
Free Cash Flow
CDXS
CDXS
ISPR
ISPR
Q4 25
$19.6M
$-4.0M
Q3 25
$-7.9M
$-1.2M
Q2 25
$-20.5M
$3.7M
Q1 25
$-15.1M
$-12.7M
Q4 24
$-18.2M
$-3.2M
Q3 24
$-14.0M
$3.3M
Q2 24
$-12.6M
$-2.2M
Q1 24
$-8.9M
$3.3M
FCF Margin
CDXS
CDXS
ISPR
ISPR
Q4 25
50.3%
-19.9%
Q3 25
-91.7%
-3.9%
Q2 25
-133.6%
18.6%
Q1 25
-199.6%
-48.4%
Q4 24
-85.0%
-7.7%
Q3 24
-109.0%
8.5%
Q2 24
-157.5%
-5.9%
Q1 24
-52.2%
10.9%
Capex Intensity
CDXS
CDXS
ISPR
ISPR
Q4 25
1.3%
0.3%
Q3 25
2.1%
0.0%
Q2 25
16.4%
4.8%
Q1 25
16.7%
0.7%
Q4 24
8.3%
0.1%
Q3 24
7.8%
0.7%
Q2 24
5.0%
2.0%
Q1 24
6.6%
0.3%
Cash Conversion
CDXS
CDXS
ISPR
ISPR
Q4 25
2.09×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons